Regional Director - MSL East

Bronstein, Gewirtz & Grossman LLC urges Replimune Group, Inc. investors to act: Class Action filed alleging investor harm. Nationally recognized firm urges Replimune Investors to explore Class Action representation. NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers. "Our practice focuses on restoring investor capital and ensuring corporate accountability to uphold market integrity," said Peretz Bronstein. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Replimune securities between October 20, 2025 and April 10, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/cases/replimune-group-inc-repl-class_action_lawsuit. Replimune Case Details The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: * Replimune failed to address study design concerns previously communicated by the FDA in connection with the BLA; * Replimune submitted data from an early, unplanned analysis of RP1-104 that included only 40 patients, representing approximately 10% of the planned enrollment of 400 patients; * as a result, RPL-001-16 and RP1-104 contained deficiencies that were likely to cause the FDA to reject the BLA; and * as a result, Defendants' statements about Replimune's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. What's Next for Replimune Investors? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/cases/replimune-group-inc-repl-class_action_lawsuit. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Replimune you have until October 5, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. No Cost to Replimune Investors We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman, LLC for Replimune Securities Class Action? Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com "Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC. Contact Info Peretz Bronstein, Esq. or Nathan Miller Bronstein, Gewirtz & Grossman, LLC 917-590-0911 | [email protected] Attorney advertising. Prior results do not guarantee similar outcomes.

Replimune Group announced equity awards for Michelle DiNapoli, its chief commercial officer. The inducement grants include stock options for 150,000 shares at $15.58 per share and restricted stock units representing 100,000 shares. The stock option has a 10-year term and vests over four years, with 25% vesting after one year and the remainder monthly over three years. The restricted stock units vest in approximately four equal annual instalments beginning in August 2027. The awards were approved under Nasdaq Listing Rule 5635(c)(4) as an employment inducement. Replimune is a commercial-stage biotechnology company developing oncolytic immunotherapies, including TUDRIQEV, approved for advanced melanoma treatment.

Replimune hires Genentech veteran to lead melanoma launch. Replimune has installed a former Genentech executive as chief commercial officer days after an accelerated approval for its melanoma therapy, while Neumora's Paul Berns hands off the CEO title. Replimune named Michelle DiNapoli, a former Genentech executive, as chief commercial officer effective Aug. 18, weeks after winning a new accelerated approval for its melanoma therapy; REPL traded at 14.57, up 3.70%, as of 13:51 GMT on Aug. 21, 2026. Replimune (REPL) has hired Michelle DiNapoli as chief commercial officer, effective Aug. 18, filling the most consequential open seat at a company that has just cleared the hardest hurdle in its history: a new accelerated approval for its melanoma therapy. DiNapoli arrives from a career that includes time at Genentech, one of the industry's deepest benches for oncology commercial talent. The timing is the message. Companies do not recruit a commercial chief for an abstraction. They recruit one when there is a label to sell against, a payer conversation to open, and a field force to stand up before revenue is expected to appear. Replimune's approval was hard-fought - the phrasing used by Endpoints News in reporting the appointment - and a hard-fought approval usually leaves a narrower label and a more sceptical prescribing audience than a clean first-pass clearance would. What a chief commercial officer actually has to build. For a first-launch oncology company, the commercial chief owns four things that all have to land in roughly the same quarter. First, pricing and gross-to-net: the list price, the discounts negotiated with payers and group purchasing organisations, and the patient-assistance structure that determines what the company actually collects. Second, market access - getting the product onto payer formularies and, for a physician-administered therapy, into hospital and infusion-centre buying processes, which is a separate and slower fight than a retail pharmacy listing. Third, the field organisation: sales representatives, medical science liaisons and reimbursement specialists who help oncology practices navigate coding and coverage. Fourth, distribution - specialty pharmacy or specialty distributor relationships, and cold-chain logistics where the product demands it. Each of those has a lead time measured in months, which is why the hire lands before the launch rather than after it. A Genentech background is a specific signal here. Genentech's commercial model in oncology has historically been built around deep account-level engagement with academic cancer centres and large community oncology networks, rather than breadth-first primary-care selling. That is the right muscle memory for a novel melanoma therapy, where the initial prescribing base is likely to be concentrated in a relatively small number of high-volume centres. Accelerated approval sets the clock, not just the label. Accelerated approval is a conditional pathway. The Food and Drug Administration grants it on the basis of an endpoint judged reasonably likely to predict clinical benefit, on the understanding that the sponsor will complete confirmatory work. That creates a dual obligation for Replimune: commercialise now, and continue generating the evidence that keeps the approval in place. The commercial consequence is that pricing and access decisions get made under a cloud of conditionality. Payers know the approval is provisional and can price that risk into coverage policy - prior authorisation requirements, step edits, restrictions to the exact patient population in the label. A commercial chief with large-cap oncology experience is precisely the profile a board recruits to argue against those restrictions from the first payer meeting rather than the third. For investors, the practical question is not whether the approval happened but how quickly it converts. Watch for the first disclosed net revenue quarter, the number of ordering accounts, and any management commentary on gross-to-net erosion. Those are the metrics that separate an approval from a franchise. The share price is off the mat, not out of the woods. REPL changed hands at 14.57 as of 13:51 GMT on Aug. 21, 2026, up 3.70% on the day from a previous close of 14.05, with an intraday range of 13.81 to 14.67. That is a firmer move than the broad market managed on the same session: the S&P 500 tracker SPY was at $765.08, up 0.33%, the Nasdaq 100 proxy QQQ at $711.88, up 0.13%, and the Dow tracker DIA at $530.70, up 0.60%. Outperforming the index on the day of a commercial-hire announcement is not, by itself, a verdict on the therapy. Small-cap biotech trades on narrative velocity, and a credible senior hire is a low-cost, high-visibility signal that management believes there is something worth selling. The harder test comes when the company has to put a number next to it. Neumora's Berns steps back from the CEO title. Outperforming the index on the day of a commercial-hire announcement is not, by itself, a verdict on the therapy. Separately, Paul Berns is shedding the chief executive title at Neumora (NMRA). The shares traded at 1.54 as of 13:51 GMT on Aug. 21, 2026, up 1.65% from a previous close of 1.51, in a day range of 1.51 to 1.56. A share price at that level tells its own story about where the market has put the company. Sub-$2 biotech equities typically reflect a combination of clinical disappointment, financing pressure, or both, and a change at the top is the standard corporate response. Whether Berns's departure from the CEO role represents a planned handover or a board-driven reset is not something the disclosure settles. What matters operationally is continuity of the pipeline and the balance sheet. Leadership changes at small biotechs frequently precede a strategic review - a reprioritisation of programmes, a partnering push, or in harder cases a sale or wind-down. Shareholders should look for whether the successor is an internal promotion, which usually signals continuity, or an external appointment with turnaround credentials, which usually does not. Two companies, two points on the same curve. Set side by side, Replimune and Neumora illustrate the two directions a clinical-stage biotech can travel. One has cleared the regulator and is now spending on the apparatus of selling - a commercial chief, and behind that title a payroll of field staff, market-access specialists and distribution contracts that did not exist a year ago. The other is changing its leader with the market valuing it in low single digits per share. The connective tissue is that both moves are, at bottom, about credibility with capital. Replimune is signalling that the approval is real enough to build a company around. Neumora is signalling that the current configuration needs changing. In a sector where funding conditions have punished companies without a clear path to revenue, the personnel page has become a leading indicator that investors read as closely as the clinical one. The next disclosures to watch are Replimune's first commentary on launch metrics and pricing, and Neumora's naming of who takes the chief executive role and on what mandate. Key facts. * REPL price: 14.57, +3.70% as of 13:51 GMT, Aug. 21, 2026 * New hire: Michelle DiNapoli, chief commercial officer, effective Aug. 18 * NMRA price: 1.54, +1.65% as of 13:51 GMT, Aug. 21, 2026 * Leadership change: Neumora's Paul Berns sheds the CEO title Frequently asked questions. Who is Replimune's new chief commercial officer? Michelle DiNapoli, whose appointment took effect Aug. 18. She previously worked at Genentech, a company with one of the industry's deepest oncology commercial organisations. Her mandate at Replimune is to build the pricing, market-access, field-force and distribution apparatus needed to launch the company's newly approved melanoma therapy. What does accelerated approval mean for Replimune? Accelerated approval is a conditional US pathway in which the FDA clears a drug on an endpoint reasonably likely to predict clinical benefit, with the sponsor obliged to complete confirmatory work. It allows commercial sales to begin sooner but leaves the approval provisional, which payers can factor into coverage restrictions and prior-authorisation requirements. How did Replimune shares trade on the day of the announcement? REPL traded at 14.57 as of 13:51 GMT on Aug. 21, 2026, up 3.70% from a previous close of 14.05, within an intraday range of 13.81 to 14.67. That outpaced the broad market that session, with the S&P 500 tracker up 0.33% and the Nasdaq 100 proxy up 0.13%. What is happening at Neumora? Paul Berns is giving up the chief executive title at Neumora. The company's shares traded at 1.54 as of 13:51 GMT on Aug. 21, 2026, up 1.65% from a previous close of 1.51. The disclosure does not settle whether the change is a planned handover or a board-driven reset. Why do biotechs hire a commercial chief before launch? Because the work has long lead times. Setting list price and negotiating discounts, securing payer formulary placement, recruiting a specialised field organisation and arranging specialty distribution each take months. A company that waits until the product is available to start that work forfeits early revenue and cedes ground to competing therapies. What should investors watch next at Replimune? The first quarter in which net product revenue is disclosed, the number of ordering accounts or treating centres, management commentary on gross-to-net discounting, and progress on the confirmatory evidence required to convert the accelerated approval into a full one. Those metrics, not the approval itself, determine whether a launch becomes a franchise.